Cancer diagnostics group VolitionRx (NYSE:VNRX) is to present at the LD Micro Conference, Los Angeles this week.
At the conference, David Kratochvil, chief financial officer and treasurer, and Scott Powell, vice president of IR, will outline the company’s business milestones, plans and commercialisation strategy for its NuQ blood-based tests for colorectal cancer (CRC).
Additionally, they will discuss clinical developments, including the impressive results from ongoing trials for both pancreatic cancer and lung cancer.
Pancreatic is second type of cancer for which VolitionRx currently expects to bring a NuQ panel test to market, following CRC.